The prevalence of preeclampsia in this study is similar to that seen in other prospective cohort studies recruiting women with suspected preeclampsia.11, 16, 20 Women in all categories of the initial PlGF test change category, demonstrating that PlGF is a dynamic biomarker at the time of suspected clinical disease and there may be utility in repeated testing beyond the test performed at the initial clinical presentation. This evidence concerns the gene PGF and preeclampsia.